- Home
- RA vs GERN Comparison
RA vs GERN Comparison
Compare RA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- GERN
- Stock Information
- Founded
- RA 2016
- GERN 1990
- Country
- RA United States
- GERN United States
- Employees
- RA 1260
- GERN N/A
- Industry
- RA Investment Managers
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- RA Finance
- GERN Health Care
- Exchange
- RA Nasdaq
- GERN Nasdaq
- Market Cap
- RA 711.7M
- GERN 853.5M
- IPO Year
- RA N/A
- GERN 1996
- Fundamental
- Price
- RA $13.08
- GERN $1.53
- Analyst Decision
- RA
- GERN Buy
- Analyst Count
- RA 0
- GERN 7
- Target Price
- RA N/A
- GERN $4.17
- AVG Volume (30 Days)
- RA 280.8K
- GERN 10.2M
- Earning Date
- RA 01-01-0001
- GERN 08-07-2025
- Dividend Yield
- RA 14.73%
- GERN N/A
- EPS Growth
- RA N/A
- GERN N/A
- EPS
- RA N/A
- GERN N/A
- Revenue
- RA N/A
- GERN $116,293,000.00
- Revenue This Year
- RA N/A
- GERN $160.12
- Revenue Next Year
- RA N/A
- GERN $55.01
- P/E Ratio
- RA N/A
- GERN N/A
- Revenue Growth
- RA N/A
- GERN 22264.04
- 52 Week Low
- RA $11.89
- GERN $1.17
- 52 Week High
- RA $17.32
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- RA 63.22
- GERN 52.39
- Support Level
- RA $12.81
- GERN $1.42
- Resistance Level
- RA $12.94
- GERN $1.57
- Average True Range (ATR)
- RA 0.08
- GERN 0.09
- MACD
- RA 0.02
- GERN -0.01
- Stochastic Oscillator
- RA 91.38
- GERN 40.74
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.